Many biological markers are associated with poor prognosis in chronic lymphocytic leukemia (CLL), but their mechanistic role remains unclear. Bax is an essential proapoptotic protein and decreased levels in malignant cells lead to resistance to apoptosis. 
Introduction
The clinical course of B-cell chronic lymphocytic leukemia (CLL) is highly heterogeneous. Disease progression and survival correlate not only with clinical parameters, but also with a plethora of biological prognostic markers, including immunoglobulin (Ig) heavy chain variable gene (VH) mutation status, 1,2 ZAP-70,
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CD38 expression. 1 Recurrent cytogenetic abnormalities, with loss of the short arm of chromosome 17 (17p deletion), confer a very poor prognosis 6 with the presumed mechanism of action involving (at least) loss of p53. Furthermore, functional loss of p53 activity, even in cases without a detectable p53 mutation, has been suggested as one mechanism underlying the poor prognosis associated with unmutated Ig VH genes. 7 The molecular mechanisms underlying the worse prognosis in CLL with unmutated Ig VH, ZAP-70 or CD38 expression also remain elusive, although enhanced cell signaling/survival have been implicated.
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The role of ZAP-70 in enhancing signaling has been questioned in recent work showing that B-cell receptor triggering was not influenced by the ZAP-70 status of CLL cells. 11 Clearly, further work is required to elucidate the cellular and molecular mechanisms that underlie the observed clinical value of these prognostic markers.
Fundamental to all malignant cells is the property of uncontrolled cell growth, often combined with resistance to apoptosis -a characteristic feature of CLL cells. A key pro-apoptotic protein is Bax, with low levels of, or absent, Bax expression in malignant cells being associated with resistance to treatment. Several pro-apoptotic molecules have been shown to be regulated by the ubiquitin/proteasome pathway, including p53, 12 Bid, and cell lines, 15,18 as well as primary CLL cells. 19 In the accompanying paper (Liu et al 
Materials and Methods

Cell culture and clinical samples
The protocol was approved by our local Ethical Committee. by polyacrylamide gel electrophoresis and clonal PCR products were purified using QIAquick PCR purification kits (QIAGEN), followed by direct sequencing twice with the consensus primer to the joining region on an ABI 377 DNA sequencer. In cases where direct sequencing failed, PCR products were cloned and at least four clones were sequenced using vector primers. The consensus sequence in each case was subjected to database search for identification of the variable (V), diversity (D) and joining (J) germline segments used and somatic mutation in the rearranged V segment using DNAPLOT and VBASE2 (http://www.vbase2.org/).
Prognostic markers in CLL: cytogenetic analyses
Interphase FISH analysis was performed using the commercially available Vysis CLL probes (Abbott Diagnostics) to detect the common CLL associated abnormalities;
deletions of ATM (11q23), D13S319 (13q14) and p53 (17p13), trisomy 12 using a chromosome 12 centromere probe (CEP12). FISH was also set up to exclude the presence of the t (11;14) , ICH/CCND1 associated with mantle cell lymphoma. The probes were applied as dual colour probe pair sets (ATM/p53, D13S319/CEP12 and IGH/CCND1) and used according to the manufacturers protocol. For each probe set, 100 interphases were scored on Leica DMXRA microscope fitted with a COHU CCD camera using MacProbe V4.1.1 CGH software (PSI/Applied Imaging).
In vitro Bax degradation assay
CLL cells were incubated in the Buffer A (250 mM sucrose, 10 mM HEPES-KOH, pH 
Western blotting
In order to assess Bax expression, CLL cells were placed in lysis buffer (1% Triton X-100, 0.5% sodium deoxycholate, 0.1 SDS, 1 mM PMFS, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM sodium orthovanadate, 1 mM DTT in PBS, pH 7.4). Proteins were subjected to standard SDS-PAGE at 20-40mA/gel and transferred on to PVDF membrane at 100 V for 1 hour. PVDF membrane was blocked with 1% non-fat milk in PBST for 1 hour and probed for various proteins using the monoclonal anti-Bax 2D2 antibody, clone 
Statistical analysis
Binary comparisons between Bax degradation activity (positive or negative) were made with Binet stage (A or not A), presence of IgV H mutation, ZAP-70 and CD38 positivity, LDT (>12 months or other), karyotype (11q-or 17p-/ other) using Chi-square with Yate's correction or 2-sided Fisher's Exact test, as appropriate. Survival time and time to treatment between Bax groups was compared using Kaplan-Meier plots and Cox's F test.
Multivariate analysis was undertaken using a generalized non-linear binomial model using logit analysis. Statistical significance was assumed at a p-value of < 0.05.
Results
Bax instability in CLL cells
In the accompanying paper, Bax protein levels were found to vary with individual malignant B-cell lines. This variation was not related to Bax mRNA expression, suggesting regulation at the post-translational level (Liu et al,) . A specific defect of Bax stability was found in malignant B-cells and BDA was higher in these than in control tissues. In this paper, the work has been extended to 40 cases of CLL. In these patients, 
Bax degradation activity does not correlate with Bax protein levels
It was important to establish whether the differential responses in the BDA assay were related to the baseline level of Bax protein in CLL cells. Bax protein expression was tested in 15 CLL samples -8 BDA positive and 7 BDA negative. Figure 2 shows that there was no correlation between BDA and Bax protein levels, with BDA positive and negative cases having both high and low levels of basal Bax. CD38 positive and 15% (6/40) had 11q22 or 17p13 deletions. In our diagnostic practice, with a population of nearly 2 million, ZAP-70 and CD38 positivity are typically seen in one third of cases (data not shown). Thus, this cohort of patients with CLL appears to represent a higher risk population than the general CLL population, which is in keeping with the bias of a tertiary referral center, as recognized in the literature.
Bax degradation activity is associated with poor prognostic markers in CLL
3,5
The identification of two populations of CLL cases -those in whom the cells had or 17p13 deletion cases. However, probably because of a lack of power, individually, none of these apparent associations with BDA positivity were statistically significant (Table 2) ,
Bax degradation activity is associated with poor outcomes in CLL
Median OS in the BDA positive group was 126 months, which was significantly worse than in the BDA negative group (p = 0.011) ( the balance of these two processes -however, a high level of Bax could still be associated with high degradation activity if counterbalanced by increased synthesis. As the BDA assay uses post-nuclear extracts, the synthetic arm of Bax regulation has been eliminated and the assay provides an in vitro measure of the ubiquitin/proteasome degradation activity. Thus BDA is a dynamic indicator of intrinsic ubiquitin/proteasome activity in CLL cells and is a one-way 'output' (i.e., degradation) assay -without the synthetic 'input' arm. BDA could therefore be a more robust tool for prognostication and may partly explain why the literature contains contradictory reports on the prognostic value of Bax protein measurements in CLL.
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The BDA positive cases showed a marked accumulation of known poor prognostic features, shorter overall survival and time to first treatment as compared to the BDA negative group (Table 2 and Figures 3 and 4) . 1: D13S319 = probe for 13q14, ATM = probe for 11q22, CEP12 = chromosome 12 enumeration probe, IGH\= probe for 14q32, p53 = probe for 17p13; x1 = monoallelic deletion, x0 = biallelic deletion; Normal = all FISH probes were present in two copies; Complex = more than 3 cytogenetic abnormalities;
#: complex includes loss of 9p, partial trisomy 12q, loss of 17p.
*: complex includes del (13) (q1q2) and 14q32 rearrangement. 
